关键信息
-
基因名
BIRC3
- 应用
-
别名
BIRC3；API2；MIHC；RNF49；Baculoviral IAP repeat-containing Protein 3
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q13489
-
表达区间
1-604aa
-
氨基酸序列
MNIVENSIFL SNLMKSANTF ELKYDLSCEL YRMSTYSTFP AGVPVSERSL ARAGFYYTGV NDKVKCFCCG LMLDNWKRGD SPTEKHKKLY PSCRFVQSLN SVNNLEATSQ PTFPSSVTNS THSLLPGTEN SGYFRGSYSN SPSNPVNSRA NQDFSALMRS SYHCAMNNEN ARLLTFQTWP LTFLSPTDLA KAGFYYIGPG DRVACFACGG KLSNWEPKDN AMSEHLRHFP KCPFIENQLQ DTSRYTVSNL SMQTHAARFK TFFNWPSSVL VNPEQLASAG FYYVGNSDDV KCFCCDGGLR CWESGDDPWV QHAKWFPRCE YLIRIKGQEF IRQVQASYPH LLEQLLSTSD SPGDENAESS IIHFEPGEDH SEDAIMMNTP VINAAVEMGF SRSLVKQTVQ RKILATGENY RLVNDLVLDL LNAEDEIREE ERERATEEKE SNDLLLIRKN RMALFQHLTC VIPILDSLLT AGIINEQEHD VIKQKTQTSL QARELIDTIL VKGNIAATVF RNSLQEAEAV LYEHLFVQQD IKYIPTEDVS DLPVEEQLRR LQEERTCKVC MDKEVSIVFI PCGHLVVCKD CAPSLRKCPI CRSTIKGTVR TFLS
-
分子量
68.3 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
BIRC3, also known as the Baculoviral IAP Repeat Containing 3, is a member of the inhibitor of apoptosis (IAP) family, which plays a crucial role in regulating apoptosis and cell survival. The research on BIRC3 has garnered significant attention due to its implications in various cancers, autoimmune disorders, and viral infections. BIRC3 acts by inhibiting caspases, thereby preventing programmed cell death, which can contribute to tumorigenesis when dysregulated. Additionally, it is involved in signaling pathways that influence cell proliferation and immune responses. The exploration of BIRC3 as a potential therapeutic target has become a focal point in cancer research, especially in understanding its role in resistance to chemotherapy and targeted therapies. Recent studies have demonstrated that BIRC3 can modulate the response to different treatments, making it a promising candidate for combination therapies aimed at overcoming drug resistance. The development of BIRC3 recombinant proteins provides valuable tools for studying its functional mechanisms, interactions with other cellular proteins, and potential as a biomarker for disease prognosis. The continued investigation into the role of BIRC3 in various biological processes and disease states is essential for advancing therapeutic strategies and improving patient outcomes in oncology and immunology.
